CD47 and pulmonary arterial hypertension: Similarly, in pulmonary arterial hypertension (PAH), antibody-mediated CD47 blockade lowers right ventricular systolic pressure and attenuates hypertrophy, effects attributed partly to suppression of TSP1 and restoration of caveolin-1 levels in pulmonary tissue [119].